Admission to Euronext

 

TIDMCRYO 
 
RNS Number : 1879B 
Cryo-Save Group NV 
22 October 2009 
 

This announcement and the information contained herein is not for release, 
publication or distribution, directly or indirectly, in or into the United 
States, Australia, Canada, Japan, South Africa or any jurisdiction in which the 
same would be unlawful. This announcement is not an offer of securities in the 
United States, Canada, South Africa, Australia, Japan or any other jurisdiction. 
 
 
 
 
22 October 2009 
 
 
Cryo-Save Group NV 
 
 
Admission to trading on Euronext Amsterdam 
 
 
Cryo-Save Group N.V. (AIM/EURONEXT: CRYO, "Cryo-Save", "the Company"), Europe's 
leading stem cell bank, today announces commencement of dealings of its ordinary 
shares on Euronext Amsterdam by NYSE Euronext.  Cryo-Save's ISIN code is 
NL0009272137. 
 
 
The prospectus is available free of charge at the Company's offices in Zutphen, 
the Netherlands and can be downloaded from the Company's website, 
www.cryo-savegroup.com. 
 
 
 
 
+-------------------------------------+----------------------------------+ 
| For further details:                |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| Cryo-Save Group                     |             + 31 (0) 575 548998  | 
+-------------------------------------+----------------------------------+ 
| Marc Waeterschoot, Chief Executive  |                                  | 
| Arnoud van Tulder, Chief Financial  |                                  | 
| Officer                             |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| Daniel Stewart & Company plc        |           + 44 (0) 20 7776 6550  | 
+-------------------------------------+----------------------------------+ 
| Simon Leathers                      |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| Kempen & Co                         |              [phone] | 
+-------------------------------------+----------------------------------+ 
| Ivo Piest                           |                                  | 
+-------------------------------------+----------------------------------+ 
|                                     |                                  | 
+-------------------------------------+----------------------------------+ 
| College Hill                        |           + 44 (0) 20 7457 2020  | 
+-------------------------------------+----------------------------------+ 
| Adrian Duffield/Rozi Morris         |                                  | 
+-------------------------------------+----------------------------------+ 
 
 
About Cryo-Save 
 
 
With more than 115,000 samples saved, Cryo-Save is the leading stem cell bank in 
Europe and one of the fastest growing in the world. Driven by its international 
business strategy, Cryo-Save is now represented in 38 countries on three 
continents and has state-of-the-art processing facilities in Belgium, Germany, 
Dubai, India and France (under construction). 
 
 
Cryo-Save sets the highest quality standards in stem cell storage, as it aims to 
make an important contribution to conquer possible life-threatening diseases in 
the future. As a service to the public, Cryo-Save offers a Cost-free Family 
Donation Programme, free of charge, to families wishing to store their newborn's 
umbilical cord blood stem cells for a family member diagnosed with a 
life-threatening disease treatable by stem cells. The company is committed to 
further improve stem cell cryopreservation techniques, by participating in 
European Commission funded projects, in Universities and Hospitals. 
The paying and settlement agent of Cryo-Save is Kempen & Co. N.V., 
Beethovenstraat 300, 1077 WZ Amsterdam, the Netherlands. 
 
 
The information contained herein is not for publication or distribution, 
directly or indirectly, in or into the United States of America (including its 
territories and possessions, any State of the United States and the District of 
Columbia). These materials do not contain or constitute an offer for sale or the 
solicitation of an offer to purchase securities in the United States or any 
other jurisdiction. The securities mentioned herein have not been and will not 
be registered under the U.S. Securities Act of 1933, as amended (the "Securities 
Act"), and may not be offered or sold in the United States absent registration 
under the Securities Act or an available exemption from, or transaction not 
subject to, the registration requirements of the Securities Act. 
 
This announcement is not a prospectus. In connection with the admission of the 
shares in the capital of the Company to trading on Euronext Amsterdam by NYSE 
Euronext, a prospectus has been made generally available. Copies of the 
Prospectus are available at no cost through the website of the Company 
(www.cryo-savegroup.com) and the website of Euronext Amsterdam (Dutch residents 
only) and by sending a request in writing to the Company at its business 
address: IJsselkade 8, 7201 HB Zutphen, the Netherlands. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCEASEFASKNFFE